Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CryoCath Technologies
Position in strategic surgical ablation market fortified with alliance
May 14th, 2003
CryoCath Technologies, Inc., (CYT) announced that it has reached an agreement with Endocare, Inc., to acquire the exclusive and permanent global rights to SurgiFrost, a surgical probe system to ablate cardiac arrhythmias, a rapidly growing market with worldwide sales expected to exceed U.S.$250 million within 5 years. "The overwhelmingly positive physician response and clinical success since launching SurgiFrost a year ago mandated that we fully control this system to optimize its commercial potential," said Steven G. Arless, president and CEO. "Moreover, this transaction's strategic potential to bolster our catheter-based business can only serve to increase our...
Source: Biotech Week (2003-05-14)
|
